Adherence to treatment with injectable immunomodulators in patients with multiple sclerosis and cognitive disorder

Wiendl, 2008, Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations, J Neurol, 255, 1449, 10.1007/s00415-008-0061-1 Gross, 2019, Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies, Continuum (Minneap Minn), 25, 715 Morillo Verdugo, 2019, Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain, Patient Prefer Adherence, 13, 261, 10.2147/PPA.S187983 Fernández, 2012, Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain, PLoS One, 7, e35600, 10.1371/journal.pone.0035600 Câmara, 2017, Factors associated with adherence to immunomodulator treatment in people with multiple esclerosis, Braz J Pharm Sci, 53, 10.1590/s2175-97902017000116132 Corallo, 2019, Therapeutic adherence and coping strategies in patients with multiple sclerosis: an observational study, Medicine (Baltimore), 98, e16532, 10.1097/MD.0000000000016532 Bartolomé García, 2019, Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis, Eur J Hosp Pharm, 26, 23, 10.1136/ejhpharm-2017-001286 Iturbe, 2012, Discontinuación y adherencia a largo plazo en la terapia con interferón beta en pacientes con esclerosis múltiple, Farm Hosp, 36, 77, 10.1016/j.farma.2010.12.006 Alegre Ayala, 2008, Esclerósis múltiple: alteraciones cognitivas y actividades de la vida diaria, TOG (A Coruña), 5, 1 Koutsouraki, 2019, Cognitive decline in multiple sclerosis patients, Hell J Nucl Med., 22, 75 Compston, 2002, Multiple sclerosis, Lancet, 359, 1221, 10.1016/S0140-6736(02)08220-X Oreja-Guevara, 2019, Cognitive dysfunctions and assessments in multiple sclerosis, Front Neurol, 10, 581, 10.3389/fneur.2019.00581 Benedict, 2017, Multiple sclerosis outcome assessments consortium. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis, Mult Scler, 23, 721, 10.1177/1352458517690821 Patel, 2017, Deconstructing the symbol digit modalities test in multiple sclerosis: the role of memory, Mult Scler Relat Disord, 17, 184, 10.1016/j.msard.2017.08.006 Cancela, 2012, Valores normativos del «Symbol Digit Modalities Test» de aplicación en poblaciones españolas residentes en geriátricos: un estudio piloto, Actas Esp Psiquiatr, 40, 299 Halpern, 2011, Comparación de la adherencia y la persistencia entre pacientes con sclerosis multiple tratados con modificadores de la Enfermedad terapias: un análisis retrospectivo de las reivindicaciones administrativos La adherencia del paciente, Prefiero, 5, 73 Costello, 2008, Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term, Medscape J Med, 10, 225 McKay, 2017, Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study, Mult Scler, 23, 588, 10.1177/1352458516657440 Rae-Grant, 2019, Incorporating clinical practice guidelines and quality measures into high-quality cost-effective care for patients with multiple sclerosis, Continuum (Minneap Minn), 25, 845